KYNTRA BIO, INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 05/31/23 | FY 05/08/23 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $6.4M | $29.6M | $46.8M | — | — |
| Cost of revenue | $556,000 | $15.6M | $4.0M | — | — |
| Selling, general & administrative | $27.7M | $49.3M | $86.5M | — | — |
| Research and development | $23.5M | $95.7M | $266.5M | — | — |
| Operating income | -$45.9M | -$150.4M | -$322.7M | — | — |
| Interest expense | $8.8M | $8.2M | $8.1M | — | — |
| Pretax income | -$58.3M | -$153.4M | -$323.2M | — | — |
| Income tax expense | -$90,000 | -$269,000 | -$252,000 | — | — |
| Net income | $183.5M | -$47.6M | -$284.2M | — | — |
| Balance Sheet | |||||
| Cash and equivalents | $47.9M | $50.5M | $81.6M | — | — |
| Current assets | $99.1M | $196.5M | $331.6M | — | — |
| Total assets | $119.6M | $214.5M | $423.5M | — | — |
| Current liabilities | $29.2M | $133.3M | $217.7M | — | — |
| Total liabilities | $115.1M | $398.2M | $585.7M | — | — |
| Total debt | — | — | — | $74.1M | $74.1M |
| Stockholders' equity | -$30.0M | -$225.6M | -$204.2M | — | — |
| Cash Flow Statement | |||||
| Cash from operations | -$4.8M | -$138.0M | -$315.0M | — | — |
| Depreciation and amortization | $713,000 | $2.7M | $9.5M | — | — |
| Stock-based compensation | $6.6M | $25.2M | $50.8M | — | — |
| Capital expenditure | $38,000 | $266,000 | $2.5M | — | — |
| Free cash flow | -$4.8M | -$138.3M | -$317.5M | — | — |
| Impairments | — | $0 | $0 | — | — |
Shares outstanding 4.0M · Free float 95.8%
Annual filing data through FY ended December 31, 2025; float as of July 11, 2026.